Bill > H4211

This bill aims to improve patient access to cancer clinical trial programs. It defines key terms such as "cancer clinical trials," "inducement," "subject," and "travel and ancillary costs." The bill clarifies that reimbursement of a subject's travel and ancillary costs will not be considered an inducement or undue influence to participate in a cancer clinical trial. Sponsors of cancer clinical trials are required to inform potential subjects about the availability of reimbursement for travel and ancillary costs, including based on financial need, to eliminate financial barriers to enrollment. The bill also allows governmental entities, study sponsors, public and private foundations, corporations, and individuals to offer financial support to cover travel and ancillary costs through third-party nonprofit corporations and public charities. Lastly, the bill requires that reimbursement programs be reviewed and approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) of a healthcare facility.

Health and Social Services

Joint Committee on Public Health (J)

https://malegislature.gov/Bills/191/H4211